Plasma Substance P Levels in Patients with Persistent Cough

Otsuka, Kojiro; Niimi, Akio; Matsumoto, Hisako; Ito, Isao; Yamaguchi, Masafumi; Matsuoka, Hiroaki; Jinnai, Makiko; Oguma, Tsuyoshi; Takeda, Takumi; Nakaji, Hitoshi; Chin, Kazuo; Sasaki, Kazuhiko; Aoyama, Norihito; Mishima, Michiaki

doi:10.1159/000330419

Cited by 36 publications

(29 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have also reported that plasma levels of substance P are elevated in patients with CVA and cough-predominant asthma as compared with healthy subjects [47]. cys-LTs induce the release of substance P through the stimulation of airway afferent nerve fibers [48], and LTRAs inhibit such release [48,49].…”

Section: Discussionmentioning

confidence: 99%

Clinical, Physiological and Anti-Inflammatory Effect of Montelukast in Patients with Cough Variant Asthma

Takemura¹,

Niimi²,

Matsumoto³

et al. 2011

Respiration

Self Cite

View full text Add to dashboard Cite

Background: Cough variant asthma (CVA) is a phenotype of asthma presenting solely with coughing, characterized by airway hyperresponsiveness, eosinophilic inflammation and a cough response to bronchodilators. Leukotriene receptor antagonists (LTRAs) are antiasthma medications with anti-inflammatory and bronchodilatory properties. Although LTRAs exert antitussive effects in CVA, the mechanisms involved are unknown. Objectives: This study aimed to clarify the antitussive mechanisms of LTRAs in CVA patients. Methods: We prospectively observed the effect of montelukast (10 mg) daily for 4 weeks in 23 consecutive nonsmoking adults with anti-inflammatory treatment-naive CVA. We evaluated, before and after treatment, the cough visual analogue scale (VAS), pulmonary function (spirometry and impulse oscillation), methacholine airway responsiveness, cough receptor sensitivity, expressed by the concentration of capsaicin inducing 2 or more (C2) and 5 or more (C5) coughs, sputum eosinophil counts and levels of inflammatory mediators, including cysteinyl leukotrienes, leukotriene B₄, prostaglandin (PG) D₂, PGE₂, PGF₂_α and thromboxane B₂. We compared the baseline characteristics of the patients based on the symptomatic response to montelukast, defined as a decrease in the cough VAS of >25% (n = 15) or ≤25% (n = 8). Results: Montelukast significantly decreased the cough VAS (p = 0.0008), sputum eosinophil count (p = 0.013) and cough sensitivity (C2: p = 0.007; C5: p = 0.039), whereas pulmonary function, airway responsiveness and sputum mediator levels remained unchanged. Multivariate analysis showed that a better response to montelukast was associated solely with younger age (p = 0.032). Conclusion: The antitussive effect of montelukast in CVA may be attributed to the attenuation of eosinophilic inflammation rather than its bronchodilatory properties.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical, Physiological and Anti-Inflammatory Effect of Montelukast in Patients with Cough Variant Asthma

Takemura¹,

Niimi²,

Matsumoto³

et al. 2011

Respiration

Self Cite

View full text Add to dashboard Cite

show abstract

“…Interestingly, elevated SP levels were also found in the plasma (Otsuka et al, 2011) and nasal secretions (Cho et al, 2003) of patients with chronic cough. Indeed, it was postulated that elevated SP in nasal secretions defines a distinct population of patients with chronic cough, those with "upper airway cough syndrome" (Lim et al, 2011).…”

Section: B Transient Receptor Potential Channels Inmentioning

confidence: 94%

Transient Receptor Potential Channels as Drug Targets: From the Science of Basic Research to the Art of Medicine

2014

View full text Add to dashboard Cite

“…This correlates with increased levels of nitrosative stress, which enhances Substance P secretion [80]. Increased Substance P is also found in the plasma of chronic cough sufferers [81]. …”

Section: Reviewmentioning

confidence: 99%

Molecular signaling and targets from itch: lessons for cough

LaVinka

Dong

2013

Cough

View full text Add to dashboard Cite

Itch is described as an unpleasant sensation that elicits the desire to scratch, which results in the removal of the irritant from the skin. The cough reflex also results from irritation, with the purpose of removing said irritant from the airway. Could cough then be similar to itch? Anatomically, both pathways are mediated by small-diameter sensory fibers. These cough and itch sensory fibers release neuropeptides upon activation, which leads to inflammation of the nerves. Both cough and itch also involve mast cells and their mediators, which are released upon degranulation. This common inflammation and interaction with mast cells are involved in the development of chronic conditions of itch and cough. In this review, we examine the anatomy and molecular mechanisms of itch and compare them to known mechanisms for cough. Highlighting the common aspects of itch and cough could lead to new thoughts and perspectives in both fields.

show abstract

Plasma Substance P Levels in Patients with Persistent Cough

Cited by 36 publications

References 98 publications

Clinical, Physiological and Anti-Inflammatory Effect of Montelukast in Patients with Cough Variant Asthma

Clinical, Physiological and Anti-Inflammatory Effect of Montelukast in Patients with Cough Variant Asthma

Transient Receptor Potential Channels as Drug Targets: From the Science of Basic Research to the Art of Medicine

Molecular signaling and targets from itch: lessons for cough

Contact Info

Product

Resources

About